Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 11,822 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Treatment Efficacy Clear all
Not listed Phase 3 Interventional

Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

NCT01204801
View directory record Official record
Conditions
Breast Cancer
Interventions
Focused Microwave Thermotherapy, Chemotherapy (control)
Device · Drug
Lead sponsor
Medifocus, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 19, 2026, 10:55 AM EDT
Not listed Not applicable Interventional

Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects

NCT01860612
View directory record Official record
Conditions
Full Aniridia, Partial Aniridia
Interventions
Artificial Iris (CustomFlex)
Device
Lead sponsor
Clinical Research Consultants, Inc.
Industry
Eligibility
3 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
13
States / cities
Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 19, 2026, 10:55 AM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration

NCT00089830
View directory record Official record
Conditions
Macular Degeneration
Interventions
MSI-1256F (Squalamine Lactate)
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
50 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Plymouth Meeting, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2007 · Synced Oct 19, 2026, 10:55 AM EDT
Completed Not applicable Interventional Results available

TrueRelief Efficacy for Post-cesarean Pain (ELECTRON)

NCT05250830
View directory record Official record
Conditions
Post-cesarean Pain
Interventions
TrueRelief device, Sham TrueRelief device
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 19, 2026, 10:55 AM EDT
Completed Phase 3 Interventional

Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT00552565
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Rezular 15mg, Placebo, Rezular
Drug
Lead sponsor
AGI Therapeutics, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2009 · Synced Oct 19, 2026, 10:55 AM EDT
Completed Not applicable Interventional

Home-Based Functional Exercise Program in Patients With Patellar Femoral Syndrome Over a 10-Week Period

NCT03407365
View directory record Official record
Conditions
Patellar Femoral Syndrome
Interventions
10 Week Exercise Program, DVD Program After 10 Weeks
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 19, 2026, 10:55 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer

NCT01090830
View directory record Official record
Conditions
Non-Small-Cell Lung Carcinoma
Interventions
Belinostat, carboplatin, paclitaxel and bevacizumab
Drug
Lead sponsor
Holy Cross Hospital, Florida
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 19, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Study of Obeldesivir in Nonhospitalized Participants With COVID-19

NCT05715528
View directory record Official record
Conditions
COVID-19
Interventions
Obeldesivir, Obeldesivir Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
12 Years to 64 Years
Enrollment
2,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
108
States / cities
Alabaster, Alabama • Chandler, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 19, 2026, 10:55 AM EDT
Terminated Phase 1 Interventional

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

NCT06406400
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
AZD4041, Itraconazole, Buprenorphine, Buprenorphine / Naloxone, Hydromorphone, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2025 · Synced Oct 19, 2026, 10:55 AM EDT
Completed Phase 3 Interventional

Topical Antifungal Treatment for Tinea Pedis

NCT01396811
View directory record Official record
Conditions
Tinea Pedis
Interventions
33525, Placebo
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
12 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Miami, Florida • Miramar, Florida • Augusta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 19, 2026, 10:55 AM EDT
Recruiting No phase listed Observational

Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions

NCT07737171
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA)
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
60 participants
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 19, 2026, 10:55 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Evaluating Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors

NCT00415571
View directory record Official record
Conditions
Hypogonadism, Erectile Dysfunction
Interventions
Fispemifene (once daily for 8 weeks)
Drug
Lead sponsor
QuatRx Pharmaceuticals Company
Industry
Eligibility
20 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2010 · Synced Oct 19, 2026, 10:55 AM EDT
Completed Phase 1Phase 2 Interventional

LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients

NCT04261387
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
LUT014 Gel, Placebo for LUT014 Gel
Drug
Lead sponsor
Lutris Pharma Ltd.
Industry
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Columbus, Georgia • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 19, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of Granulocyte Transfusions in Resolving Infection in People With Neutropenia (The RING Study)

NCT00627393
View directory record Official record
Conditions
Neutropenia, Infection
Interventions
Standard antimicrobial therapy, Granulocyte transfusions, G-CSF/dexamethasone, Apheresis machine
Drug · Biological · Device
Lead sponsor
Carelon Research
Other
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
13
States / cities
Iowa City, Iowa • Baltimore, Maryland • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 19, 2026, 10:55 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS

NCT00722800
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
drospirenone and ethinyl estradiol (YAZ), Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 19, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

NCT04186871
View directory record Official record
Conditions
Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome
Interventions
branebrutinib, abatacept, branebrutinib placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Covina, California • Encino, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 19, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis

NCT01186744
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
666 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
50
States / cities
Mobile, Alabama • Tucson, Arizona • Fremont, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2018 · Synced Oct 19, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

Effectiveness of Oral Prednisone in Improving Physical Functioning and Decreasing Pain in People With Sciatica

NCT00668434
View directory record Official record
Conditions
Sciatica
Interventions
Prednisone, Placebo
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years to 70 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Redwood City, California • Roseville, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Oct 19, 2026, 10:55 AM EDT
Completed Phase 1 Interventional

The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis

NCT00002316
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Lobradimil, Amphotericin B
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
11
States / cities
Los Angeles, California • Orange, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 19, 2026, 10:55 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer

NCT00598312
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide Acetate for Injectable Suspension
Drug
Lead sponsor
Oakwood Laboratories, LLC
Industry
Eligibility
45 Years and older · Male only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Oakwood Village, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 8, 2010 · Synced Oct 19, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

NCT02034019
View directory record Official record
Conditions
Post Ocular Surgical Inflammation and Pain
Interventions
Dexamethasone, Punctum Plug
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 19, 2026, 10:55 AM EDT
Terminated Phase 3 Interventional Results available

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors

NCT00372567
View directory record Official record
Conditions
Gastrointestinal Stromal Tumor
Interventions
sunitinib malate, imatinib mesylate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Detroit, Michigan • Farmington Hills, Michigan • City of Saint Peters, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2011 · Synced Oct 19, 2026, 10:55 AM EDT
Terminated Phase 3 Interventional

Neocartilage Implant to Treat Cartilage Lesions of the Knee

NCT01400607
View directory record Official record
Conditions
Articular Cartilage Disorder, Degeneration; Articular Cartilage, Chronic Cartilage Injury, Acute Cartilage Injury, Defect of Articular Cartilage
Interventions
Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft), Microfracture
Biological · Other
Lead sponsor
ISTO Technologies, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Santa Monica, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Oct 19, 2026, 10:55 AM EDT
Completed Phase 1 Interventional

Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

NCT01301807
View directory record Official record
Conditions
Non-Secretory Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Carfilzomib, Panobinostat
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 19, 2026, 10:55 AM EDT